Pulmonary function tests
PFTs were performed within 2 weeks before day 1 of rituximab therapy and repeated 6 months after day 14 of rituximab therapy. Predicted diffusing capacity of the lung for carbon monoxide (DLCO) and FVC was measured using a MS-PFT analyzer (Jaeger, Wuerzburg, Germany) in accordance with European Respiratory Society guidelines [